HIV drug trogarzo gets a speed boost: new shorter injections tested
NCT ID NCT03913195
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether Trogarzo, an HIV medication, can be given as a quick 30-second injection into a vein or as a shot into a muscle, instead of the usual 15-minute infusion. Researchers enrolled 43 people, including some with HIV and some healthy volunteers, to check safety and drug levels. The goal is to make treatment more convenient for patients with multi-drug resistant HIV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ibalizumab-uiyk (Trogarzo)
What this could lead to
If successful, this could make Trogarzo easier and faster to administer, potentially improving convenience for people living with HIV who need this treatment.
What could go wrong
This is a small, completed safety study (43 people) testing different ways to give a drug already approved for multi-drug resistant HIV. It does not test whether Trogarzo works better than current options, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anthony Mills MD Inc.
Los Angeles, California, 90069, United States
-
Gary Richmond MD, PA
Fort Lauderdale, Florida, 33316, United States
-
North Texas Infectious Disease Consultants
Dallas, Texas, 75246, United States
-
Orlando Immunology Center
Orlando, Florida, 32803, United States